Form 8-K - Current report:
SEC Accession No. 0001564590-22-022684
Filing Date
2022-06-07
Accepted
2022-06-07 16:07:01
Documents
12
Period of Report
2022-06-03
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K ubx-8k_20220603.htm   iXBRL 8-K 31032
  Complete submission text file 0001564590-22-022684.txt   159948

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ubx-20220603.xsd EX-101.SCH 5610
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ubx-20220603_lab.xml EX-101.LAB 19317
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ubx-20220603_pre.xml EX-101.PRE 11499
6 EXTRACTED XBRL INSTANCE DOCUMENT ubx-8k_20220603_htm.xml XML 3555
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38470 | Film No.: 221001290
SIC: 2834 Pharmaceutical Preparations